Michael T. Hemann, Ph.D. - Publications

Johns Hopkins University, Baltimore, MD 
Telomeres and telomerase in chromosome maintenance and stability

114 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Roux B, Vaganay C, Vargas JD, Alexe G, Benaksas C, Pardieu B, Fenouille N, Ellegast JM, Malolepsza E, Ling F, Sodaro G, Ross L, Pikman Y, Conway AS, Tang Y, ... ... Hemann MT, et al. Targeting acute myeloid leukemia dependency on VCP-mediated DNA repair through a selective second-generation small-molecule inhibitor. Science Translational Medicine. 13. PMID 33790022 DOI: 10.1126/scitranslmed.abg1168  0.4
2020 Jiang T, Sánchez-Rivera FJ, Soto-Feliciano YM, Yang Q, Song CQ, Bhuatkar A, Haynes CM, Hemann MT, Xue W. Targeting de novo purine synthesis pathway via ADSL depletion impairs liver cancer growth by perturbing mitochondrial function. Hepatology (Baltimore, Md.). PMID 33336367 DOI: 10.1002/hep.31685  0.52
2020 Chatterjee N, Whitman MA, Harris CA, Min SM, Jonas O, Lien EC, Luengo A, Vander Heiden MG, Hong J, Zhou P, Hemann MT, Walker GC. REV1 inhibitor JH-RE-06 enhances tumor cell response to chemotherapy by triggering senescence hallmarks. Proceedings of the National Academy of Sciences of the United States of America. PMID 33168727 DOI: 10.1073/pnas.2016064117  0.36
2020 Liu Y, Shi N, Regev A, He S, Hemann MT. Integrated regulatory models for inference of subtype-specific susceptibilities in glioblastoma. Molecular Systems Biology. 16: e9506. PMID 32974985 DOI: 10.15252/msb.20209506  0.32
2020 Qi R, Wang Y, Bruno PM, Xiao H, Yu Y, Li T, Lauffer S, Wei W, Chen Q, Kang X, Song H, Yang X, Huang X, Detappe A, Matulonis U, ... ... Hemann MT, et al. Author Correction: Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer. Nature Communications. 11: 1940. PMID 32303677 DOI: 10.1038/S41467-020-14903-Y  0.56
2020 Bruno PM, Lu M, Dennis KA, Inam H, Moore CJ, Sheehe J, Elledge SJ, Hemann MT, Pritchard JR. The primary mechanism of cytotoxicity of the chemotherapeutic agent CX-5461 is topoisomerase II poisoning. Proceedings of the National Academy of Sciences of the United States of America. PMID 32041867 DOI: 10.1073/Pnas.1921649117  1
2019 Dalin S, Sullivan MR, Lau AN, Grauman-Boss B, Mueller HS, Kreidl E, Fenoglio S, Luengo A, Lees JA, Vander Heiden MG, Lauffenburger DA, Hemann MT. Deoxycytidine Release from Pancreatic Stellate Cells Promotes Gemcitabine Resistance. Cancer Research. PMID 31484670 DOI: 10.1158/0008-5472.Can-19-0960  1
2019 Liu Y, Hemann MT. A dynamic view of chemotherapy effectiveness. Nature. 572: 321-322. PMID 31406309 DOI: 10.1038/D41586-019-02336-7  0.32
2019 Wojtaszek JL, Chatterjee N, Najeeb J, Ramos A, Lee M, Bian K, Xue JY, Fenton BA, Park H, Li D, Hemann MT, Hong J, Walker GC, Zhou P. A Small Molecule Targeting Mutagenic Translesion Synthesis Improves Chemotherapy. Cell. PMID 31178121 DOI: 10.1016/J.Cell.2019.05.028  1
2019 Lossos C, Liu Y, Kolb KE, Christie AL, van Scoyk A, Prakadan SM, Shigemori K, Stevenson KE, Morrow S, Plana OD, Fraser C, Jones KL, Liu H, Pallasch CP, Modiste R, ... ... Hemann MT, et al. Mechanisms of lymphoma clearance induced by high-dose alkylating agents. Cancer Discovery. PMID 31040105 DOI: 10.1158/2159-8290.Cd-18-1393  0.32
2019 Dowling C, Dillion E, Hemann M, Cagney G, Letai A, Chonghaile TN. Abstract 5186: Discovery of a novel histone deacetylase 6 inhibitor that kills drug-resistant breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-5186  1
2018 Benajiba L, Alexe G, Su A, Raffoux E, Soulier J, Hemann MT, Hermine O, Itzykson R, Stegmaier K, Puissant A. Creatine kinase pathway inhibition alters GSK3 and WNT signaling in EVI1-positive AML. Leukemia. PMID 30390009 DOI: 10.1038/S41375-018-0291-X  0.4
2018 Fiedler ERC, Bhutkar A, Lawler E, Besada R, Hemann MT. In vivo RNAi screening identifies as a target for combination therapy with TKIs in BCP-ALL. Blood Advances. 2: 1229-1242. PMID 29853524 DOI: 10.1182/Bloodadvances.2017015610  0.32
2018 Wagner FF, Benajiba L, Campbell AJ, Weïwer M, Sacher JR, Gale JP, Ross L, Puissant A, Alexe G, Conway A, Back M, Pikman Y, Galinsky I, DeAngelo DJ, Stone RM, ... ... Hemann MT, et al. Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia. Science Translational Medicine. 10. PMID 29515000 DOI: 10.1126/Scitranslmed.Aam8460  0.4
2018 Qi R, Wang Y, Bruno PM, Xiao H, Yu Y, Li T, Lauffer S, Wei W, Chen Q, Kang X, Song H, Yang X, Huang X, Detappe A, Matulonis U, ... ... Hemann MT, et al. Publisher Correction: Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer. Nature Communications. 9: 628. PMID 29416025 DOI: 10.1038/S41467-018-02963-0  0.56
2018 Ramos A, Barea LRM, Puissant A, Fenouille N, Alexe G, Stegmaier K, Hemann MT. Abstract 2358: Uncovering novel mechanisms of resistance in AML using integrative functional genomics Cancer Research. 78: 2358-2358. DOI: 10.1158/1538-7445.Am2018-2358  1
2017 Qi R, Wang Y, Bruno PM, Xiao H, Yingjie Y, Li T, Lauffer S, Wei W, Chen Q, Kang X, Song H, Yang X, Huang X, Detappe A, Matulonis U, ... ... Hemann MT, et al. Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer. Nature Communications. 8: 2166. PMID 29255160 DOI: 10.1038/S41467-017-02390-7  0.56
2017 Braun CJ, Stanciu M, Boutz PL, Patterson JC, Calligaris D, Higuchi F, Neupane R, Fenoglio S, Cahill DP, Wakimoto H, Agar NYR, Yaffe MB, Sharp PA, Hemann MT, Lees JA. Coordinated Splicing of Regulatory Detained Introns within Oncogenic Transcripts Creates an Exploitable Vulnerability in Malignant Glioma. Cancer Cell. PMID 28966034 DOI: 10.1016/J.Ccell.2017.08.018  0.36
2017 Tang YC, Yuwen H, Wang K, Bruno PM, Bullock K, Deik AA, Santaguida S, Trakala M, Pfau SJ, Zhong N, Huang T, Wang L, Clish CB, Hemann MT, Amon A. Aneuploid cell survival relies upon sphingolipid homeostasis. Cancer Research. PMID 28775166 DOI: 10.1158/0008-5472.Can-17-0049  0.56
2017 Ramos A, Hemann MT. Drugs, Bugs, and Cancer: Fusobacterium nucleatum Promotes Chemoresistance in Colorectal Cancer. Cell. 170: 411-413. PMID 28753421 DOI: 10.1016/J.Cell.2017.07.018  1
2017 Soto-Feliciano YM, Bartlebaugh JME, Liu Y, Sánchez-Rivera FJ, Bhutkar A, Weintraub AS, Buenrostro JD, Cheng CS, Regev A, Jacks TE, Young RA, Hemann MT. PHF6 regulates phenotypic plasticity through chromatin organization within lineage-specific genes. Genes & Development. PMID 28607179 DOI: 10.1101/Gad.295857.117  0.52
2017 Bruno PM, Liu Y, Park GY, Murai J, Koch CE, Eisen TJ, Pritchard JR, Pommier Y, Lippard SJ, Hemann MT. A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. Nature Medicine. PMID 28263311 DOI: 10.1038/Nm.4291  1
2017 Fenouille N, Bassil CF, Ben-Sahra I, Benajiba L, Alexe G, Ramos A, Pikman Y, Conway AS, Burgess MR, Li Q, Luciano F, Auberger P, Galinsky I, DeAngelo DJ, Stone RM, ... ... Hemann MT, et al. The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia. Nature Medicine. PMID 28191887 DOI: 10.1038/Nm.4283  1
2017 Dalin S, Zhao B, Hemann MT. Abstract PR07: Collateral sensitivity in chemotherapy resistance Molecular Cancer Therapeutics. 16. DOI: 10.1158/1538-8514.Synthleth-Pr07  1
2016 Zhao B, Hemann MT, Lauffenburger DA. Modeling Tumor Clonal Evolution for Drug Combinations Design. Trends in Cancer. 2: 144-158. PMID 28435907 DOI: 10.1016/J.Trecan.2016.02.001  1
2016 Sun D, Dalin S, Hemann MT, Lauffenburger DA, Zhao B. Differential selective pressure alters rate of drug resistance acquisition in heterogeneous tumor populations. Scientific Reports. 6: 36198. PMID 27819268 DOI: 10.1038/Srep36198  1
2016 Zheng YR, Suntharalingam K, Bruno PM, Lin W, Wang W, Hemann MT, Lippard SJ. Mechanistic Studies of the Anticancer Activity of An Octahedral Hexanuclear Pt(II) Cage. Inorganica Chimica Acta. 452: 125-129. PMID 27818526 DOI: 10.1016/J.Ica.2016.03.021  0.56
2016 Eskandari A, Boodram JN, Cressey PB, Lu C, Bruno PM, Hemann MT, Suntharalingam K. The breast cancer stem cell potency of copper(ii) complexes bearing nonsteroidal anti-inflammatory drugs and their encapsulation using polymeric nanoparticles. Dalton Transactions (Cambridge, England : 2003). PMID 27774561 DOI: 10.1039/C6Dt03811E  0.56
2016 Barnes JC, Bruno PM, Nguyen HV, Liao L, Liu J, Hemann MT, Johnson JA. Using an RNAi Signature Assay To Guide the Design of Three-Drug-Conjugated Nanoparticles with Validated Mechanisms, In Vivo Efficacy, and Low Toxicity. Journal of the American Chemical Society. PMID 27626288 DOI: 10.1021/Jacs.6B06321  0.56
2016 Pikman Y, Puissant A, Alexe G, Furman A, Chen LM, Frumm SM, Ross L, Fenouille N, Bassil CF, Lewis CA, Ramos A, Gould J, Stone RM, DeAngelo DJ, Galinsky I, ... ... Hemann MT, et al. Targeting MTHFD2 in acute myeloid leukemia. The Journal of Experimental Medicine. PMID 27325891 DOI: 10.1084/Jem.20151574  0.56
2016 Braun CJ, Bruno PM, Horlbeck MA, Gilbert LA, Weissman JS, Hemann MT. Versatile in vivo regulation of tumor phenotypes by dCas9-mediated transcriptional perturbation. Proceedings of the National Academy of Sciences of the United States of America. PMID 27325776 DOI: 10.1073/Pnas.1600582113  0.56
2016 Wilson JL, Dalin S, Gosline S, Hemann M, Fraenkel E, Lauffenburger DA. Pathway-based network modeling finds hidden genes in shRNA screen for regulators of acute lymphoblastic leukemia. Integrative Biology : Quantitative Biosciences From Nano to Macro. PMID 27315426 DOI: 10.1039/C6Ib00040A  1
2016 Lindblad O, Cordero E, Puissant A, Macaulay L, Ramos A, Kabir NN, Sun J, Vallon-Christersson J, Haraldsson K, Hemann MT, Borg Å, Levander F, Stegmaier K, Pietras K, Rönnstrand L, et al. Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML. Oncogene. PMID 26999641 DOI: 10.1038/Onc.2016.41  1
2016 Zhao B, Sedlak JC, Srinivas R, Creixell P, Pritchard JR, Tidor B, Lauffenburger DA, Hemann MT. Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution. Cell. PMID 26924578 DOI: 10.1016/J.Cell.2016.01.045  1
2016 Awuah SG, Zheng YR, Bruno PM, Hemann MT, Lippard SJ. Correction to "A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy". Journal of the American Chemical Society. PMID 26916820 DOI: 10.1021/Jacs.6B01316  0.56
2016 Boodram JN, Mcgregor IJ, Bruno PM, Cressey PB, Hemann MT, Suntharalingam K. Breast Cancer Stem Cell Potent Copper(II)-Non-Steroidal Anti-Inflammatory Drug Complexes. Angewandte Chemie (International Ed. in English). PMID 26806362 DOI: 10.1002/Anie.201510443  0.56
2016 Dalin S, Zhao B, Hemann MT. Abstract 35: Evolution of resistance to glucocorticoid receptor agonists Clinical Cancer Research. 22: 35-35. DOI: 10.1158/1557-3265.Pmsclingen15-35  1
2016 Soto-Feliciano YM, Bartlebaugh JM, Liu Y, Sánchez-Rivera FJ, Weintraub AS, Bhutkar A, Jacks TE, Young RA, Hemann MT. Abstract A44: The role of PHF6 in maintaining pre-B cell commitment in B-cell acute lymphoblastic leukemia Cancer Research. 76. DOI: 10.1158/1538-7445.Chromepi15-A44  0.52
2016 Zhao B, Hemann MT, Lauffenburger DA. Modeling tumor clonal evolution for drug combinations design Trends in Cancer. 2: 144-158. DOI: 10.1016/j.trecan.2016.02.001  1
2016 Zheng YR, Suntharalingam K, Bruno PM, Lin W, Wang W, Hemann MT, Lippard SJ. Mechanistic studies of the anticancer activity of an octahedral hexanuclear Pt(II) cage Inorganica Chimica Acta. 452: 125-129. DOI: 10.1016/j.ica.2016.03.021  0.56
2015 Cannell IG, Merrick KA, Morandell S, Zhu CQ, Braun CJ, Grant RA, Cameron ER, Tsao MS, Hemann MT, Yaffe MB. A Pleiotropic RNA-Binding Protein Controls Distinct Cell Cycle Checkpoints to Drive Resistance of p53-Defective Tumors to Chemotherapy. Cancer Cell. PMID 26602816 DOI: 10.1016/j.ccell.2015.09.009  1
2015 Shingleton JR, Hemann MT. The Chromatin Regulator CHD8 Is a Context-Dependent Mediator of Cell Survival in Murine Hematopoietic Malignancies. Plos One. 10: e0143275. PMID 26588464 DOI: 10.1371/Journal.Pone.0143275  1
2015 Awuah SG, Zheng YR, Bruno PM, Hemann MT, Lippard SJ. A Platinum(IV) Pro-drug Preferentially Targets IDO Providing Enhanced Ovarian Cancer Immuno-Chemotherapy. Journal of the American Chemical Society. PMID 26561720 DOI: 10.1021/Jacs.5B10182  0.56
2015 McFaline-Figueroa JL, Braun CJ, Stanciu M, Nagel ZD, Mazzucato P, Sangaraju D, Cerniauskas E, Barford K, Vargas A, Chen Y, Tretyakova N, Lees JA, Hemann MT, White FM, Samson LD. Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide. Cancer Research. PMID 26025730 DOI: 10.1158/0008-5472.Can-14-3616  1
2015 Liu C, Ding H, Li X, Pallasch CP, Hong L, Guo D, Chen Y, Wang D, Wang W, Wang Y, Hemann MT, Jiang H. A DNA/HDAC dual-targeting drug CY190602 with significantly enhanced anticancer potency. Embo Molecular Medicine. 7: 438-49. PMID 25759362 DOI: 10.15252/Emmm.201404580  0.56
2015 Meacham CE, Lawton LN, Soto-Feliciano YM, Pritchard JR, Joughin BA, Ehrenberger T, Fenouille N, Zuber J, Williams RT, Young RA, Hemann MT. A genome-scale in vivo loss-of-function screen identifies Phf6 as a lineage-specific regulator of leukemia cell growth. Genes & Development. 29: 483-8. PMID 25737277 DOI: 10.1101/Gad.254151.114  0.56
2015 Suntharalingam K, Awuah SG, Bruno PM, Johnstone TC, Wang F, Lin W, Zheng YR, Page JE, Hemann MT, Lippard SJ. Necroptosis-inducing rhenium(V) oxo complexes. Journal of the American Chemical Society. 137: 2967-74. PMID 25698398 DOI: 10.1021/Ja511978Y  0.56
2015 Zhao B, Hemann MT, Lauffenburger DA. Abstract A31: Combination therapies guided by evolution of tumor heterogeneity. Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Hemmal14-A31  1
2015 Bruno PM, Park GY, Murai J, Liu Y, Pritchard J, Pommier Y, Lippard SJ, Hemann MT. Abstract C56: Platinum containing anti-cancer agents as targeted therapeutics Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-C56  0.56
2015 Hemann M. Chimeric tumor and organ transplantation models Cold Spring Harbor Protocols. 2015: 725-730. DOI: 10.1101/Pdb.Top069872  1
2015 Hemann M. Loss-of-function screening in hematopoietic malignancies Cold Spring Harbor Protocols. 2015: 740-742. DOI: 10.1101/Pdb.Prot078022  1
2015 Hemann M. Syngeneic transplants with modified chimeric hematopoietic tumors Cold Spring Harbor Protocols. 2015: 735-739. DOI: 10.1101/Pdb.Prot078014  1
2014 Zhao B, Hemann MT, Lauffenburger DA. Reply to Azuaje: Predicting effective combined therapies for heterogeneous tumors. Proceedings of the National Academy of Sciences of the United States of America. 111: E4288. PMID 25253893 DOI: 10.1073/Pnas.1415737111  0.56
2014 Suntharalingam K, Lin W, Johnstone TC, Bruno PM, Zheng YR, Hemann MT, Lippard SJ. A breast cancer stem cell-selective, mammospheres-potent osmium(VI) nitrido complex. Journal of the American Chemical Society. 136: 14413-6. PMID 25247635 DOI: 10.1021/Ja508808V  0.56
2014 Zhao B, Hemann MT, Lauffenburger DA. Intratumor heterogeneity alters most effective drugs in designed combinations. Proceedings of the National Academy of Sciences of the United States of America. 111: 10773-8. PMID 25002493 DOI: 10.1073/Pnas.1323934111  0.56
2014 Hemann MT. From breaking bad to worse: exploiting homologous DNA repair deficiency in cancer. Cancer Discovery. 4: 516-8. PMID 24795010 DOI: 10.1158/2159-8290.Cd-14-0316  0.56
2014 Puissant A, Fenouille N, Alexe G, Pikman Y, Bassil CF, Mehta S, Du J, Kazi JU, Luciano F, Rönnstrand L, Kung AL, Aster JC, Galinsky I, Stone RM, DeAngelo DJ, ... Hemann MT, et al. SYK is a critical regulator of FLT3 in acute myeloid leukemia. Cancer Cell. 25: 226-42. PMID 24525236 DOI: 10.1016/J.Ccr.2014.01.022  0.56
2014 Pallasch CP, Leskov I, Braun CJ, Vorholt D, Drake A, Soto-Feliciano YM, Bent EH, Schwamb J, Iliopoulou B, Kutsch N, van Rooijen N, Frenzel LP, Wendtner CM, Heukamp L, Kreuzer KA, ... ... Hemann MT, et al. Sensitizing protective tumor microenvironments to antibody-mediated therapy. Cell. 156: 590-602. PMID 24485462 DOI: 10.1016/J.Cell.2013.12.041  0.56
2014 Zhao B, Pritchard JR, Lauffenburger DA, Hemann MT. Addressing genetic tumor heterogeneity through computationally predictive combination therapy. Cancer Discovery. 4: 166-74. PMID 24318931 DOI: 10.1158/2159-8290.Cd-13-0465  0.56
2014 Pallasch C, Gilbert L, Hemann M. Abstract IA10: Improving existing cancer therapy by targeting the tumor microenvironment Molecular Cancer Research. 12. DOI: 10.1158/1557-3125.Modorg-Ia10  1
2014 Sánchez-Rivera FJ, Ryan J, Soto-Feliciano YM, Feldser DM, Hemann MT, Letai A, Jacks T. Abstract 2961: The level of mitochondrial apoptotic priming determines cell fate upon p53 restoration Cancer Research. 74: 2961-2961. DOI: 10.1158/1538-7445.Am2014-2961  0.52
2013 Suntharalingam K, Johnstone TC, Bruno PM, Lin W, Hemann MT, Lippard SJ. Bidentate ligands on osmium(VI) nitrido complexes control intracellular targeting and cell death pathways. Journal of the American Chemical Society. 135: 14060-3. PMID 24041161 DOI: 10.1021/Ja4075375  0.56
2013 Wilson JL, Hemann MT, Fraenkel E, Lauffenburger DA. Integrated network analyses for functional genomic studies in cancer. Seminars in Cancer Biology. 23: 213-8. PMID 23811269 DOI: 10.1016/J.Semcancer.2013.06.004  0.56
2013 Braun CJ, Hemann MT. Unraveling tumor suppressor networks with in vivo RNAi. Cell Stem Cell. 12: 639-41. PMID 23746971 DOI: 10.1016/J.Stem.2013.05.020  0.56
2013 Pavlova NN, Pallasch C, Elia AE, Braun CJ, Westbrook TF, Hemann M, Elledge SJ. A role for PVRL4-driven cell-cell interactions in tumorigenesis. Elife. 2: e00358. PMID 23682311 DOI: 10.7554/Elife.00358  0.56
2013 Pritchard JR, Bruno PM, Hemann MT, Lauffenburger DA. Predicting cancer drug mechanisms of action using molecular network signatures. Molecular Biosystems. 9: 1604-19. PMID 23287973 DOI: 10.1039/C2Mb25459J  0.56
2013 Pritchard JR, Bruno PM, Gilbert LA, Capron KL, Lauffenburger DA, Hemann MT. Defining principles of combination drug mechanisms of action. Proceedings of the National Academy of Sciences of the United States of America. 110: E170-9. PMID 23251029 DOI: 10.1073/Pnas.1210419110  0.56
2013 Leskov I, Pallasch CP, Drake A, Iliopoulou BP, Souza A, Shen CH, Schweighofer CD, Abruzzo L, Frenzel LP, Wendtner CM, Hemann MT, Chen J. Rapid generation of human B-cell lymphomas via combined expression of Myc and Bcl2 and their use as a preclinical model for biological therapies. Oncogene. 32: 1066-72. PMID 22484426 DOI: 10.1038/Onc.2012.117  0.56
2013 Pavlova NN, Pallasch C, Elia AE, Braun CJ, Westbrook TF, Hemann M, Elledge SJ. Author response: A role for PVRL4-driven cell–cell interactions in tumorigenesis Elife. DOI: 10.7554/Elife.00358.038  1
2013 Fenoglio S, Soto-Feliciano Y, Hannon G, Hemann M. Abstract A234: In vivo RNAi screening to identify major players in pancreatic tumor maintenance and growth. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-A234  1
2013 Lauffenburger DA, Zhao B, Pritchard JR, Hemann MT. Abstract IA10: Targeting intratumoral genetic heterogeneity through rationally designed combination therapy Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Pms-Ia10  1
2012 Pritchard JR, Lauffenburger DA, Hemann MT. Understanding resistance to combination chemotherapy. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 15: 249-57. PMID 23164555 DOI: 10.1016/J.Drup.2012.10.003  1
2012 Gilbert LA, Hemann MT. Context-specific roles for paracrine IL-6 in lymphomagenesis. Genes & Development. 26: 1758-68. PMID 22855834 DOI: 10.1101/Gad.197590.112  0.56
2012 Lauffenburger DA, Pritchard JR, Hemann MT. Abstract SY22-02: Mammalian functional genetic signatures identify efficacy landscapes of combination chemotherapy Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Sy22-02  1
2012 Sánchez-Rivera FJ, Feldser DM, Doench J, Bhutkar A, Meacham CE, Root DE, Hemann MT, Jacks T. Abstract 2957: Uncovering tumor-specific components of the p53 pathway using mouse models and RNAi Cancer Research. 72: 2957-2957. DOI: 10.1158/1538-7445.Am2012-2957  0.52
2012 Hemann MT. The development and use of genetically tractable preclinical mouse models Genetically Engineered Mice For Cancer Research: Design, Analysis, Pathways, Validation and Pre-Clinical Testing. 477-495. DOI: 10.1007/978-0-387-69805-2_23  1
2011 Pritchard JR, Gilbert LA, Meacham CE, Ricks JL, Jiang H, Lauffenburger DA, Hemann MT. Bcl-2 family genetic profiling reveals microenvironment-specific determinants of chemotherapeutic response. Cancer Research. 71: 5850-8. PMID 21784872 DOI: 10.1158/0008-5472.Can-11-1014  1
2011 Gilbert LA, Hemann MT. Chemotherapeutic resistance: surviving stressful situations. Cancer Research. 71: 5062-6. PMID 21771909 DOI: 10.1158/0008-5472.Can-11-0277  1
2011 Stadanlick JE, Zhang Z, Lee SY, Hemann M, Biery M, Carleton MO, Zambetti GP, Anderson SJ, Oravecz T, Wiest DL. Developmental arrest of T cells in Rpl22-deficient mice is dependent upon multiple p53 effectors. Journal of Immunology (Baltimore, Md. : 1950). 187: 664-75. PMID 21690328 DOI: 10.4049/Jimmunol.1100029  1
2011 Jiang H, Pritchard JR, Williams RT, Lauffenburger DA, Hemann MT. A mammalian functional-genetic approach to characterizing cancer therapeutics. Nature Chemical Biology. 7: 92-100. PMID 21186347 DOI: 10.1038/Nchembio.503  1
2010 Feldser DM, Kostova KK, Winslow MM, Taylor SE, Cashman C, Whittaker CA, Sanchez-Rivera FJ, Resnick R, Bronson R, Hemann MT, Jacks T. Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature. 468: 572-5. PMID 21107428 DOI: 10.1038/Nature09535  1
2010 Xie K, Doles J, Hemann MT, Walker GC. Error-prone translesion synthesis mediates acquired chemoresistance. Proceedings of the National Academy of Sciences of the United States of America. 107: 20792-7. PMID 21068378 DOI: 10.1073/Pnas.1011412107  1
2010 Doles J, Oliver TG, Cameron ER, Hsu G, Jacks T, Walker GC, Hemann MT. Suppression of Rev3, the catalytic subunit of Pol{zeta}, sensitizes drug-resistant lung tumors to chemotherapy. Proceedings of the National Academy of Sciences of the United States of America. 107: 20786-91. PMID 21068376 DOI: 10.1073/Pnas.1011409107  1
2010 Gilbert LA, Hemann MT. DNA damage-mediated induction of a chemoresistant niche. Cell. 143: 355-66. PMID 21029859 DOI: 10.1016/J.Cell.2010.09.043  1
2010 Doles J, Hemann MT. Nek4 status differentially alters sensitivity to distinct microtubule poisons. Cancer Research. 70: 1033-41. PMID 20103636 DOI: 10.1158/0008-5472.Can-09-2113  1
2009 Bric A, Miething C, Bialucha CU, Scuoppo C, Zender L, Krasnitz A, Xuan Z, Zuber J, Wigler M, Hicks J, McCombie RW, Hemann MT, Hannon GJ, Powers S, Lowe SW. Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. Cancer Cell. 16: 324-35. PMID 19800577 DOI: 10.1016/J.Ccr.2009.08.015  1
2009 Meacham CE, Ho EE, Dubrovsky E, Gertler FB, Hemann MT. In vivo RNAi screening identifies regulators of actin dynamics as key determinants of lymphoma progression. Nature Genetics. 41: 1133-7. PMID 19783987 DOI: 10.1038/Ng.451  1
2009 Christian Reinhardt H, Jiang H, Hemann MT, Yaffe MB. Exploiting synthetic lethal interactions for targeted cancer therapy Cell Cycle. 8: 3112-3119. PMID 19755856 DOI: 10.4161/Cc.8.19.9626  1
2009 Pritchard JR, Cosgrove BD, Hemann MT, Griffith LG, Wands JR, Lauffenburger DA. Three-kinase inhibitor combination recreates multipathway effects of a geldanamycin analogue on hepatocellular carcinoma cell death. Molecular Cancer Therapeutics. 8: 2183-92. PMID 19671754 DOI: 10.1158/1535-7163.Mct-08-1203  1
2009 Jiang H, Reinhardt HC, Bartkova J, Tommiska J, Blomqvist C, Nevanlinna H, Bartek J, Yaffe MB, Hemann MT. The combined status of ATM and p53 link tumor development with therapeutic response Genes and Development. 23: 1895-1909. PMID 19608766 DOI: 10.1101/Gad.1815309  1
2008 Burgess DJ, Doles J, Zender L, Xue W, Ma B, McCombie WR, Hannon GJ, Lowe SW, Hemann MT. Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America. 105: 9053-8. PMID 18574145 DOI: 10.1073/Pnas.0803513105  1
2008 Hemann M. Abstract ED05-03: The development of tractable mouse models to study therapeutic response Cancer Prevention Research. 1. DOI: 10.1158/1940-6207.Prev-08-Ed05-03  1
2007 Mayr C, Hemann MT, Bartel DP. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science (New York, N.Y.). 315: 1576-9. PMID 17322030 DOI: 10.1126/Science.1137999  1
2007 Hemann MT, Narita M. Oncogenes and senescence: breaking down in the fast lane. Genes & Development. 21: 1-5. PMID 17210783 DOI: 10.1101/Gad.1514207  1
2006 Hemann MT, Lowe SW. The p53-Bcl-2 connection. Cell Death and Differentiation. 13: 1256-9. PMID 16710363 DOI: 10.1038/Sj.Cdd.4401962  1
2005 Dickins RA, Hemann MT, Zilfou JT, Simpson DR, Ibarra I, Hannon GJ, Lowe SW. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nature Genetics. 37: 1289-95. PMID 16200064 DOI: 10.1038/Ng1651  1
2005 Hemann MT, Bric A, Teruya-Feldstein J, Herbst A, Nilsson JA, Cordon-Cardo C, Cleveland JL, Tansey WP, Lowe SW. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature. 436: 807-11. PMID 16094360 DOI: 10.1038/Nature03845  1
2005 He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ, Hammond SM. A microRNA polycistron as a potential human oncogene. Nature. 435: 828-33. PMID 15944707 DOI: 10.1038/Nature03552  1
2005 Herbst A, Hemann MT, Tworkowski KA, Salghetti SE, Lowe SW, Tansey WP. A conserved element in Myc that negatively regulates its proapoptotic activity. Embo Reports. 6: 177-83. PMID 15678160 DOI: 10.1038/Sj.Embor.7400333  1
2005 Hemann MT, Lowe SW. P53 links tumor development to cancer therapy 25 Years of P53 Research. 339-351. DOI: 10.1007/978-1-4020-2922-6_15  1
2004 Hernando E, Nahlé Z, Juan G, Diaz-Rodriguez E, Alaminos M, Hemann M, Michel L, Mittal V, Gerald W, Benezra R, Lowe SW, Cordon-Cardo C. Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature. 430: 797-802. PMID 15306814 DOI: 10.1038/Nature02820  1
2004 Chiang YJ, Hemann MT, Hathcock KS, Tessarollo L, Feigenbaum L, Hahn WC, Hodes RJ. Expression of telomerase RNA template, but not telomerase reverse transcriptase, is limiting for telomere length maintenance in vivo. Molecular and Cellular Biology. 24: 7024-31. PMID 15282303 DOI: 10.1128/Mcb.24.16.7024-7031.2004  1
2004 Hemann MT, Zilfou JT, Zhao Z, Burgess DJ, Hannon GJ, Lowe SW. Suppression of tumorigenesis by the p53 target PUMA. Proceedings of the National Academy of Sciences of the United States of America. 101: 9333-8. PMID 15192153 DOI: 10.1073/Pnas.0403286101  1
2003 Rabinowicz PD, Palmer LE, May BP, Hemann MT, Lowe SW, McCombie WR, Martienssen RA. Genes and transposons are differentially methylated in plants, but not in mammals. Genome Research. 13: 2658-64. PMID 14656970 DOI: 10.1101/Gr.1784803  1
2003 O'Hearn SF, Huang CE, Hemann M, Zhelonkina A, Sollner-Webb B. Trypanosoma brucei RNA editing complex: band II is structurally critical and maintains band V ligase, which is nonessential. Molecular and Cellular Biology. 23: 7909-19. PMID 14560033 DOI: 10.1128/Mcb.23.21.7909-7919.2003  1
2003 Fridman JS, Hernando E, Hemann MT, de Stanchina E, Cordon-Cardo C, Lowe SW. Tumor promotion by Mdm2 splice variants unable to bind p53. Cancer Research. 63: 5703-6. PMID 14522887  1
2003 Hemann MT, Fridman JS, Zilfou JT, Hernando E, Paddison PJ, Cordon-Cardo C, Hannon GJ, Lowe SW. An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nature Genetics. 33: 396-400. PMID 12567186 DOI: 10.1038/Ng1091  1
2002 Hathcock KS, Hemann MT, Opperman KK, Strong MA, Greider CW, Hodes RJ. Haploinsufficiency of mTR results in defects in telomere elongation. Proceedings of the National Academy of Sciences of the United States of America. 99: 3591-6. PMID 11904421 DOI: 10.1073/Pnas.012549799  1
2001 Hemann MT, Strong MA, Hao LY, Greider CW. The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. Cell. 107: 67-77. PMID 11595186 DOI: 10.1016/S0092-8674(01)00504-9  1
2001 Hemann MT, Rudolph KL, Strong MA, DePinho RA, Chin L, Greider CW. Telomere dysfunction triggers developmentally regulated germ cell apoptosis. Molecular Biology of the Cell. 12: 2023-30. PMID 11452000 DOI: 10.1091/Mbc.12.7.2023  1
2001 Rusché LN, Huang CE, Piller KJ, Hemann M, Wirtz E, Sollner-Webb B. The two RNA ligases of the Trypanosoma brucei RNA editing complex: cloning the essential band IV gene and identifying the band V gene. Molecular and Cellular Biology. 21: 979-89. PMID 11158286 DOI: 10.1128/Mcb.21.4.979-989.2001  1
2000 Hemann MT, Hackett J, IJpma A, Greider CW. Telomere length, telomere-binding proteins, and DNA damage signaling. Cold Spring Harbor Symposia On Quantitative Biology. 65: 275-9. PMID 12760041 DOI: 10.1101/Sqb.2000.65.275  1
2000 Hemann MT, Greider CW. Wild-derived inbred mouse strains have short telomeres. Nucleic Acids Research. 28: 4474-8. PMID 11071935 DOI: 10.1093/Nar/28.22.4474  1
1999 Hemann MT, Greider CW. G-strand overhangs on telomeres in telomerase-deficient mouse cells. Nucleic Acids Research. 27: 3964-9. PMID 10497259 DOI: 10.1093/Nar/27.20.3964  1
Show low-probability matches.